New approaches to anticoagulation in atrial fibrillation

Current Cardiology Reports

Volumn 6, Issue 5, 2004, Pages 354-364

  Petersen, Palle ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; ANTIVITAMIN K; HIRUDIN; MELAGATRAN; THROMBIN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; EMBOLISM; GENE TARGETING; HEART ATRIUM FIBRILLATION; HUMAN; LIVER DYSFUNCTION; PHARMACODYNAMICS; REVIEW; RISK BENEFIT ANALYSIS; STROKE; STRUCTURE ANALYSIS;

EID: 4544363082     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-004-0038-3     Document Type: Review

References (66)

1. Murray CJL, Lopez AD, Mathers CD, Stein C: The global burden of disease 2000 project: aims, methods and data sources. Global Programme on Evidence for Health Policy - Discussion Papers, No. 36. Geneva: World Health Organization; 2001.
2. Public health and aging: hospitalizations for stroke among adults aged >/=65 years-United States, 2000. MMWR 2003, 52:586-589.
3. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
4. Falk RH: Atrial fibrillation. N Engl J Med 2001, 344:1067-1078.
5. Singer DE: A 60-year-old woman with atrial fibrillation. JAMA 2003, 290:2182-2189.
6. EAFT (European Atrial Fibrillation Trial) Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993, 342:1255-1262.
7. Conway DS, Heeringa J, Van Der Kuip DA, et al.: Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. Stroke 2003, 34:413-417.
8. Kahn SR, Solymoss S, Flegel KM: Nonvalvular atrial fibrillation: evidence for a prothrombotic state. CMAJ 1997, 157:673-681.
9. Kamath S, Blann AD, Caine GJ, et al.: Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation. Stroke 2002, 33:1237-1242.
10. Kamath S, Chin BS, Blann AD, Lip GY: A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation. Blood Coagul Fibrinolysis 2002, 13:627-636.
11. Kamath S, Blann AD, Chin BS, Lip GY: Platelet activation, haemorheology and thrombogenesis in acute atrial fibrillation: a comparison with permanent atrial fibrillation. Heart 2003, 89:1093-1095.
12. Conway DS, Pearce LA, Chin BS, et al.: Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002, 106:1962-1967.
13. Conway DS, Pearce LA, Chin BS, et al.: Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003, 107:3141-3145.
14. Feinberg WM, Blackshear JL, Laupacis A, et al.: Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995, 155:469-473.
15. Albers GW, Dalen JE, Laupacis A, et al.: Antithrombotic therapy in atrial fibrillation. Chest 2001, 119:194S-206S.
16. United Nations: World Population Prospects. The 2002 Revision. Highlights. No. Draft, ESA/P/WP.165. New York: United Nations; 2001.
17. Go AS, Hylek EM, Phillips KA, et al.: Prevalence of diagnosed atrial fibrillation in adults - National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001, 285:2370-2375.
18. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457.
19. Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999, 131:492-501.
20. Fuster V, Rydén LE, Asinger RW, et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol 2001, 38:1231-1265.
21. Bungard TJ, Ghali WA, Teo KK, et al.: Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000, 160:41-46.
22. Gottlieb LK, Salem-Schatz S: Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994, 154:1945-1953.
23. Gurwitz JH, Monette J, Rochon PA, et al.: Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997, 157:978-984.
24. Malik AK, Taylor AJ: Can warfarin randomized trials be reproduced in 'real life'? Adherence to warfarin guidelines for intensity of anticoagulation in a university-based warfarin clinic. South Med J 2000, 93:58-61.
25. Elg M, Gustafsson D, Carlsson S: Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999, 94:187-197.
26. Hirsh J, Dalen J, Anderson DR, et al.: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001, 119:8S-21S.
27. Ansell J, Hirsh J, Dalen J, et al.: Managing oral anticoagulant therapy. Chest 2001, 119:22S-38S.
28. Hylek EM, Go AS, Chang Y, et al.: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003, 349:1019-1026.
29. Levine MN, Raskob G, Landefeld S, Kearon C: Hemorrhagic complications of anticoagulant treatment. Chest 2001, 119:108S-121S.
30. Hylek EM, Singer DE: Risk-factors far intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994, 120:897-902.
31. Elg M, Gustafsson D, Deinum J: The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 1997, 78:1286-1292.
32. Hirsh J, Fuster V, Ansell J, Halperin JL: American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003, 107:1692-1711.
33. Tabrizi AR, Zehnbauer BA, Borecki IB, et al.: The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 2002, 194:267-273.
34. Dahlback B: Blood coagulation. Lancet 2000, 355:1627-1632.
35. Harker LA, Hanson SR, Runge MS: Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol 1995, 75:12B-17B.
36. Polack B: [Thrombin: a multifunctional enzyme]. Ann Biol Clin (Paris) 2003, 61:23-31.
37. Petersen P, Grind M, Adler J, SPORTIF II Investigators: Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability and safety study. J Am Coll Cardiol 2003, 41:1445-1451.
38. Halperin JL, and the Executive Steering Committee on behalf of the SPORTIF III and V Study Investigators: Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003, 146:431-438.
39. Executive Steering Committee on behalf of the SPORTIF V investigators: Efficacy and safety study of the oral direct thrombin inhibitor ximelagatran compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in patients with atrial fibrillation (SPORTIF V). Circulation 2003, 108:21.
40. Executive Steering Committee on behalf of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003, 362:1691-1698.
41. Colwell CW, Berkowitz SD, Davidson BE, et al.: Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003, 1:2119-2130.
42. Colwell CW, Berkowitz SD, Comp PC, et al.: Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B. Blood 2003, 102:11.
43. Eriksson BI, Agnelli G, Cohen AT, et al.: Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO III study. Thromb Haemost 2003, 89:288-296.
44. Eriksson BI, Dahl OE: Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Drugs 2004, 64:577-595.
45. Eriksson BI, Agnelli G, Cohen AT, et al.: The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolisin after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003, 1:2490-2496.
46. Eriksson BI, Bergqvist D, Kälebo P, et al.: Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002, 360:1441-1447.
47. Evans HC, Perry CM, Faulds D: Ximelagatran/melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. Drugs 2004, 64:649-678.
48. Francis CW, Davidson BL, Berkowitz SD, et al.: Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002, 137:648-655.
49. Francis CW, Berkowitz SD, Comp PC, et al.: Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement. N Engl J Med 2003, 349:1703-1712.
50. Heit JA, Colwell CW, Francis CW, et al.: Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001, 161:2215-2221.
51. Exanta™ (Ximelagatran) receives first approval. Thrombos Haemost 2004, 91:VIII.
52. Wåhlander K, Lapidus L, Olsson C-G, et al.: Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 2002, 107:93-99.
53. Eriksson H, Wåhlander K, Gustafsson D, et al.: A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003, 1:41-47.
54. Schulman S, Wåhlander K, Lundström T, et al.: Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003, 349:1713-1721.
55. Gustafsson D, Nyström J-E, Carlsson S, et al.: The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001, 101:171-181.
56. Eriksson UG, Bredberg U, Gislén K, et al.: Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003, 59:35-43.
57. Eriksson UG, Bredberg U, Hoffmann K-J, et al.: Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003, 31:294-305.
58. Johansson LC, Frison I, Logren U, et al.: Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003, 42:381-392.
59. Johansson LC, Andersson M, Fager G, et al.: No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet 2003, 42:475-484.
60. Sarich TC, Teng R, Peters GR, et al.: No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin Pharmacokinet 2003, 42:485-492.
61. Bredberg E, Andersson TB, Frison L, et al.: Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 2003, 42:765-777.
62. Wåhlander K, Eriksson-Lepkowska M, Frison L, et al.: No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003, 42:755-764.
63. Sarich TC, Johansson S, Schützer K-M, et al.: The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol. J Clin Pharmacol 2004, 44:388-393.
64. Wolzt M, Boström SL, Svensson M, et al.: Effects of the oral direct thrombin inhibitor ximelagatran on P-selectin expression and thrombin generation in atrial fibrillation. Pathophysiol Haemost Thromb 2003, 33:68-74.
65. Wolzt M, Wollbratt M, Svensson M, et al.: Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and healthy subjects. Eur J Clin Pharmacol 2003, 59:537-543.
66. Eriksson U, Bååthe S, Hamrén B, et al.: Predictable pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor, in nonvalvular atrial fibrillation patients receiving long-term treatment. Pathophysiol Haemost Thromb 2002, 32(Suppl 2):56.